Program
efpeglenatide
Also written as “HM11260C”, “Efpeglenatide SAR439977” and “efpeglenatide (SAR439977)”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hanmi Pharmaceutical | 91 open or running | phase 3since Nov 21, 2017 | Mar 23, 2010 | Nov 2027phase 3 · NCT07379333 |
| Sanofi | 40 open or running | phase 3since Apr 5, 2018 | Apr 5, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 23, 2010First study: phase 1 study in HealthyNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01093729 · 41 enrolled
- Oct 4, 2011Phase 2 study in Diabetes MellitusHanmi Pharmaceutical · NCT01452451 · 72 enrolled · United States
- Jan 30, 2014Phase 2 study in Diabetes Mellitus, Type 2Hanmi Pharmaceutical · NCT02057172 · 254 enrolled · United States
- Feb 5, 2014Phase 1 study in Diabetes MellitusHanmi Pharmaceutical · NCT02059564 · 44 enrolled · United States
- Feb 24, 20142 phase 2 studiesHanmi Pharmaceutical · NCT02081118, NCT02075281
- Nov 21, 2017Phase 3 study in Diabetes Mellitus, Type 2Hanmi Pharmaceutical · NCT03353350 · 406 enrolled · United States, Germany, Poland and more
- Apr 5, 2018Sanofi's first study: phase 3 study in Diabetes Mellitus, Type 2New to SanofiSanofi · NCT03496298 · 4,076 enrolled · United States, Argentina, Bulgaria and more
- Sep 24, 2018Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT03684642 · 908 enrolled · United States, Hungary, Poland and more
- Oct 18, 2018Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT03713684 · 370 enrolled · United States, China, Korea, Republic of
- Dec 7, 2018Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT03770728 · 312 enrolled · United States, China, Taiwan
- Dec 8, 2023Phase 3 study in ObesityHanmi Pharmaceutical · NCT06174779 · 448 enrolled · South Korea
- Jan 23, 2026Phase 3 study in Diabetes Mellitus, Type 2Hanmi Pharmaceutical · NCT07379333 · 118 planned · South Korea
Ahead
- Nov 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Hanmi Pharmaceutical · NCT07379333
TargetBeta
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07379333Diabetes Mellitus, Type 2 · South Korea | 3 | Recruiting | Hanmi Pharmaceutical | Nov 2027 | 118 |
| NCT06174779Obesity · South Korea | 3 | Completed | Hanmi Pharmaceutical | Aug 14, 2025 | 448 |
| NCT03770728Diabetes Mellitus, Type 2 · United States, China, Taiwan | 3 | Terminated | Sanofi | Nov 28, 2020 | 312 |
| NCT03713684Diabetes Mellitus, Type 2 · United States, China, Korea, Republic of | 3 | Terminated | Sanofi | Nov 20, 2020 | 370 |
| NCT03684642Diabetes Mellitus, Type 2 · United States, Hungary, Poland and more | 3 | Terminated | Sanofi | Oct 13, 2020 | 908 |
| NCT03496298Diabetes Mellitus, Type 2 · United States, Argentina, Bulgaria and more | 3 | Terminated | Sanofi | Dec 10, 2020 | 4,076 |
| NCT03353350Diabetes Mellitus, Type 2 · United States, Germany, Poland and more | 3 | Completed | Hanmi Pharmaceutical | Jan 29, 2020 | 406 |
| NCT02075281Obesity · United States | 2 | Completed | Hanmi Pharmaceutical | Jan 2015 | 297 |
| NCT02081118Diabetes Mellitus, Type 2 · United States | 2 | Completed | Hanmi Pharmaceutical | Mar 2015 | 209 |
| NCT02059564Diabetes Mellitus · United States | 1 | UNKNOWN | Hanmi Pharmaceutical | Oct 2014 | 44 |
| NCT02057172Diabetes Mellitus, Type 2 · United States | 2 | Completed | Hanmi Pharmaceutical | Oct 2014 | 254 |
| NCT01452451Diabetes Mellitus · United States | 2 | Completed | Hanmi Pharmaceutical | Jun 2013 | 72 |
| NCT01093729Healthy | 1 | Completed | Hanmi Pharmaceutical | Oct 2010 | 41 |
How it is read
Names in the registry
- “HM11260C”, 12 entries
- “Efpeglenatide SAR439977”, 2 entries
- “efpeglenatide (SAR439977)”, 1 entry
- “Efpeglenatide”, 1 entry
- “Efpeglenatide (SAR439977)”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 9 studies
- Obesity, 2 studies
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.